GlassScriptPhysician profile
Meena Shah
NPI 1669507877
$1,862.64
in general payments reported to CMS, 2019-2025
32 companies · $225 in 2025
The $225 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $337 · 2020: $161 · 2021: $228 · 2022: $302 · 2023: $422 · 2024: $188 · 2025: $225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $835.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $834.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $294.39 | 2019-2024 | Xifaxan |
| Abbott Laboratories | $177.23 | 2022-2025 | Aveir, Infinity, Gallant |
| Astrazeneca Pharmaceuticals LP | $112.72 | 2019-2025 | Farxiga |
| Nestle Healthcare Nutrition INC. | $93.69 | 2021-2022 | |
| Vifor Pharma, INC. | $86.49 | 2019-2023 | Veltassa |
| Novartis Pharmaceuticals Corporation | $85.58 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $82.39 | 2019-2023 | Eliquis |
| Amgen INC. | $78.11 | 2019-2024 | Repatha |
| Cvrx, INC. | $76.03 | 2025 | Barostim Neo System |
| Pfizer INC. | $74.61 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $71.05 | 2021-2023 | Verquvo, Belsomra |
| Janssen Pharmaceuticals, INC | $63.62 | 2019-2023 | Xarelto |
| Argenx US, INC. | $50.41 | 2022-2023 | Vyvgart |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $49.47 | 2020-2024 | Lifevest |
| Abbvie INC. | $43.63 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $43.33 | 2020 | |
| Boston Scientific Corporation | $37.07 | 2019-2025 | Acuity Steerable |
| Aimmune Therapeutics, INC. | $36.06 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.62 | 2024-2025 | |
| Novo Nordisk INC | $34.97 | 2020-2023 | Ozempic, Rybelsus |
| Alexion Pharmaceuticals, INC. | $30.13 | 2019 | |
| Braintree Laboratories, INC. | $27.71 | 2022 | |
| Ardelyx, INC. | $23.64 | 2024 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.67 | 2019 | |
| Lilly USA, LLC | $21.20 | 2022 | |
| Corcept Therapeutics | $20.60 | 2025 | Korlym |
| Biohaven Pharmaceutical Holding Company LTD. | $17.65 | 2022 | |
| Arbor Pharmaceuticals, INC. | $16.28 | 2021 | |
| Exact Sciences Corporation | $15.31 | 2025 | Cologuard Collection Kit |
| Supernus Pharmaceuticals, INC. | $14.65 | 2025 | Qelbree |
| Biogen, INC. | $14.04 | 2023 | Vumerity |
| Shire North American Group INC | $13.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meena Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.